Compare Flagstar Bank NA (FLG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs TG Therapeutics Inc — how do they compare? Flagstar Bank NA trades at $11.32 (market cap $4.71B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Flagstar Bank NA pays a 0.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and TG Therapeutics Inc for 16 Days on average.
| FLG | TGTX | |
|---|---|---|
Market Cap | $4.71B | $8.16B |
Volume | 7,410,589 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $15.36 | $59.06 |
52-Week Low | $10.72 | $26.94 |
Typical Hold Time | 22 Days | 16 Days |
Enterprise Value | $15.25B | $8.37B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.32, showing modest daily gains of 0.18%. The stock faces bearish technical signals with all moving averages indicating selling pressure, though oscillators are neutral. Fundamentally, the company reported a Q2 2026 earnings miss but maintains profitability with a net income margin of 2.3%. Recent developments include a strategic core banking partnership with Fiserv and a $250 million share repurchase program announced in July 2026.
Analyst consensus remains bullish with a $17.07 price target (60% buy ratings), suggesting significant upside potential. However, risks include recent earnings volatility, high P/E ratio of 378, and negative operating cash flow in 2025. The stock trades below book value (P/B 0.62), offering value opportunity if operational improvements continue.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
